FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2081755248> ?p ?o ?g. }

• W2081755248 endingPage "269" @default.
• W2081755248 startingPage "267" @default.
• W2081755248 abstract "<h3>Background</h3> Elevated C-reactive protein (CRP) is often used as an entry criterion in clinical trials (CT) of patients (pts) with rheumatoid arthritis (RA), resulting in the potential exclusion of pts with active disease and high screen failure rates¹. <h3>Objectives</h3> To assess the relevance of requiring an elevated CRP (≥1 mg/dL) as an inclusion criterion for clinical, functional, and radiographic outcomes. <h3>Methods</h3> This <i>post hoc</i> analysis used data from 2 randomized CTs in RA pts with an inadequate response to methotrexate (MTX). In DE019, pts on background MTX received adalimumab (ADA) or placebo (PBO)²; in MUSICA, pts received either 7.5 or 20 mg MTX, along with ADA³. Data from MUSICA were used to confirm observations from DE019. Pts were subgrouped by CRP level at entry (CRP <1 mg/dL, ≥1 mg/dL). Baseline (BL) demographics and disease characteristics were summarized for each group. Clinical efficacy was assessed through swollen/tender joint count (S/TJC) at 66/68 joints, pain, patient global assessment (PtGA), physician global assessment (PhGA), CRP, clinical disease activity index (CDAI), 28-joint disease activity score based on CRP (DAS28-CRP), and proportions of pts achieving ACR20/50/70. Functional outcomes were assessed by the disability index of the health assessment questionnaire (HAQ-DI), and radiographic outcomes by the modified total Sharp score (mTSS). Outcomes were assessed in pts with CRP <0.8 mg/dL in DE019, which included pts with CRP levels as low as 0.75 mg/dL Observed data are reported at week 24. <h3>Results</h3> In DE019, 183 pts (89 and 94 in the ADA and PBO arms, respectively) had CRP <1 mg/dL and 224 pts (118 and 106, respectively) had CRP ≥1mg/dL. Pts with elevated CRP had higher BL disease activity compared with those with CRP <1 mg/dL at entry (not shown). After 24 wks of treatment with ADA, pts in both CRP subgroups experienced significant improvements in most clinical and functional outcomes vs PBO (Table). In pts with CRP <0.8 mg/dL, the ACR20 response rate difference (30.4, p<.001) and the difference in ΔmTSS (-1.3, p<.05) for ADA vs PBO treatment were still significant. Compared to pts with CRP <1 mg/dL, pts with elevated CRP experienced greater clinical and functional improvements. However, within the ADA subgroups, pts with elevated CRP had smaller differences vs PBO in mTSS, perhaps reflecting higher joint damage at BL. In general, similar trends were observed in MUSICA (not shown). <h3>Conclusions</h3> While pts with elevated CRP at entry experienced larger improvements from BL in clinical and functional outcomes upon treatment, significant improvements in most outcomes were also observed in those without elevated CRP at entry (as low as 0.75 mg/dL), suggesting that an elevated CRP may not be required to see differences between active and inactive treatment. <h3>References</h3> Von Vollenhoven et al. 2015, Arthritis Rheum 67: 2855–2860. Keystone et al. 2004. Arthritis Rheum;5:1400–11. Kaeley et al. 2016. J Rheum;8:1480–9. <h3>Acknowledgements</h3> AbbVie: study sponsor, contributed to study design, data collection, analysis and interpretation; writing, reviewing, and approval of the final version. Medical writing assistance: Naina Barretto, of AbbVie. <h3>Disclosure of Interest</h3> C. Scoville Speakers bureau: AbbVie, J. Suboticki Employee of: AbbVie, S. Zhong Employee of: AbbVie, E. Keystone Grant/research support from: AbbVie, Amgen, AstraZeneca, Biotest, Bristol-Myers Squibb, Centocor, F Hoffmann-LaRoche, Genentech, Genzyme, Merck, Novartis, Nycomed, Pfizer, and UCB., Consultant for: AbbVie, Amgen, AstraZeneca, Biotest, Bristol-Myers Squibb, Centocor, F Hoffmann-LaRoche, Genentech, Genzyme, Merck, Novartis, Nycomed, Pfizer, and UCB., Speakers bureau: AbbVie, Amgen, AstraZeneca, Biotest, Bristol-Myers Squibb, Centocor, F Hoffmann-LaRoche, Genentech, Genzyme, Merck, Novartis, Nycomed, Pfizer, and UCB." @default.
• W2081755248 created "2016-06-24" @default.
• W2081755248 creator A5021895908 @default.
• W2081755248 creator A5030258071 @default.
• W2081755248 creator A5044536188 @default.
• W2081755248 creator A5047375098 @default.
• W2081755248 date "1985-01-26" @default.
• W2081755248 modified "2023-10-16" @default.
• W2081755248 title "Circulating catecholamines in acute asthma." @default.
• W2081755248 cites W1568125009 @default.
• W2081755248 cites W1756465506 @default.
• W2081755248 cites W1966946242 @default.
• W2081755248 cites W1999459813 @default.
• W2081755248 cites W2015668200 @default.
• W2081755248 cites W2085844381 @default.
• W2081755248 cites W2086946243 @default.
• W2081755248 cites W2120365210 @default.
• W2081755248 cites W2149541517 @default.
• W2081755248 cites W2167955309 @default.
• W2081755248 cites W2262126354 @default.
• W2081755248 cites W2271327111 @default.
• W2081755248 cites W2277369354 @default.
• W2081755248 cites W2338104154 @default.
• W2081755248 cites W2419449387 @default.
• W2081755248 cites W2895749153 @default.
• W2081755248 doi "https://doi.org/10.1136/bmj.290.6464.267" @default.
• W2081755248 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1417554" @default.
• W2081755248 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3917781" @default.
• W2081755248 hasPublicationYear "1985" @default.
• W2081755248 type Work @default.
• W2081755248 sameAs 2081755248 @default.
• W2081755248 citedByCount "61" @default.
• W2081755248 countsByYear W20817552482012 @default.
• W2081755248 countsByYear W20817552482014 @default.
• W2081755248 countsByYear W20817552482016 @default.
• W2081755248 countsByYear W20817552482017 @default.
• W2081755248 countsByYear W20817552482019 @default.
• W2081755248 countsByYear W20817552482020 @default.
• W2081755248 countsByYear W20817552482022 @default.
• W2081755248 countsByYear W20817552482023 @default.
• W2081755248 crossrefType "journal-article" @default.
• W2081755248 hasAuthorship W2081755248A5021895908 @default.
• W2081755248 hasAuthorship W2081755248A5030258071 @default.
• W2081755248 hasAuthorship W2081755248A5044536188 @default.
• W2081755248 hasAuthorship W2081755248A5047375098 @default.
• W2081755248 hasBestOaLocation W20817552481 @default.
• W2081755248 hasConcept C126322002 @default.
• W2081755248 hasConcept C142724271 @default.
• W2081755248 hasConcept C1862650 @default.
• W2081755248 hasConcept C204787440 @default.
• W2081755248 hasConcept C27081682 @default.
• W2081755248 hasConcept C2776042228 @default.
• W2081755248 hasConcept C2776914184 @default.
• W2081755248 hasConcept C2777575956 @default.
• W2081755248 hasConcept C2777596629 @default.
• W2081755248 hasConcept C2780132546 @default.
• W2081755248 hasConcept C2781059491 @default.
• W2081755248 hasConcept C2781195455 @default.
• W2081755248 hasConcept C535046627 @default.
• W2081755248 hasConcept C67761136 @default.
• W2081755248 hasConcept C71924100 @default.
• W2081755248 hasConceptScore W2081755248C126322002 @default.
• W2081755248 hasConceptScore W2081755248C142724271 @default.
• W2081755248 hasConceptScore W2081755248C1862650 @default.
• W2081755248 hasConceptScore W2081755248C204787440 @default.
• W2081755248 hasConceptScore W2081755248C27081682 @default.
• W2081755248 hasConceptScore W2081755248C2776042228 @default.
• W2081755248 hasConceptScore W2081755248C2776914184 @default.
• W2081755248 hasConceptScore W2081755248C2777575956 @default.
• W2081755248 hasConceptScore W2081755248C2777596629 @default.
• W2081755248 hasConceptScore W2081755248C2780132546 @default.
• W2081755248 hasConceptScore W2081755248C2781059491 @default.
• W2081755248 hasConceptScore W2081755248C2781195455 @default.
• W2081755248 hasConceptScore W2081755248C535046627 @default.
• W2081755248 hasConceptScore W2081755248C67761136 @default.
• W2081755248 hasConceptScore W2081755248C71924100 @default.
• W2081755248 hasIssue "6464" @default.
• W2081755248 hasLocation W20817552481 @default.
• W2081755248 hasLocation W20817552482 @default.
• W2081755248 hasLocation W20817552483 @default.
• W2081755248 hasLocation W20817552484 @default.
• W2081755248 hasOpenAccess W2081755248 @default.
• W2081755248 hasPrimaryLocation W20817552481 @default.
• W2081755248 hasRelatedWork W1963607473 @default.
• W2081755248 hasRelatedWork W2006568643 @default.
• W2081755248 hasRelatedWork W2095714646 @default.
• W2081755248 hasRelatedWork W2473721473 @default.
• W2081755248 hasRelatedWork W2793666661 @default.
• W2081755248 hasRelatedWork W2945936762 @default.
• W2081755248 hasRelatedWork W3217041469 @default.
• W2081755248 hasRelatedWork W4300786425 @default.
• W2081755248 hasRelatedWork W79901769 @default.
• W2081755248 hasRelatedWork W8149610 @default.
• W2081755248 hasVolume "290" @default.
• W2081755248 isParatext "false" @default.
• W2081755248 isRetracted "false" @default.
• W2081755248 magId "2081755248" @default.
• W2081755248 workType "article" @default.